Jian Zhang
Fudan University
Emerging Leaders
not ranked
Current Leaders
#780 pts
All-Time Leaders
#29232 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2019. 22 trials as lead/chair. How it works →
Trials led — by scientific impact
A Multicenter, Randomized, Double-blind Phase III Study of PM8002 or Placebo in Combination With Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer(TNBC)
Phase 3RecruitingBiotheus Inc.Study Chair
10
impact
A Prospective, Single-arm, Single-center, Phase II Clinical Study of Triple-negative Breast Cancer Brain Metastases
Phase 2RecruitingFudan University
7
impact
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Phase 1RecruitingSichuan Baili Pharmaceutical Co., Ltd.
4
impact
A Randomized, Controlled Phase Ⅲ Study of Paclitaxel Polymeric Micelles for Injection Versus Physician's Choice(TPC) in Human Epidermal Growth Factor Receptor 2-negative (HER2-) Metastatic Breast Cancer (MBC) Subjects Who Have Failed at Least Two Previous Chemotherapy Regimens.
Phase 3RecruitingShanghai Yizhong Pharmaceutical Co., Ltd.
3
impact
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
Phase 1RecruitingFudan University
2
impact
A Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-B01D1 for Injection in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
Phase 2RecruitingSichuan Baili Pharmaceutical Co., Ltd.
2
impact
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1+PD-1 Monoclonal Antibody Combination Therapy in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
Phase 2RecruitingSichuan Baili Pharmaceutical Co., Ltd.
2
impact
Phase I/II Study of the ILB-3101 in Patients with Advanced Solid Tumors
Phase 1RecruitingInnolake Biopharm
1
impact
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Preliminary Efficacy of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumor
Phase 1RecruitingSichuan Baili Pharmaceutical Co., Ltd.
1
impact
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of TSN222 in Subjects With Advanced Solid Tumors or Lymphoma
Phase 2RecruitingTyligand Bioscience (Shanghai) Limited
1
impact
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of SI-B003 Monotherapy or BL-B01D1+SI-B003 Combination Therapy (BL-B01D1+SI-B003) in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
Phase 2RecruitingSichuan Baili Pharmaceutical Co., Ltd.
1
impact
A Phase I/II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of FWD1802in Patients With ER+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
Phase 2RecruitingForward Pharmaceuticals Co., Ltd.
0
impact
Real-world Study of Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With Antibody-drug Conjugates
N/ANot Yet RecruitingFudan University
0
impact
A Real World Study: Clinical Outcomes and Safety of Sacituzumab Govitecan in Metastatic HER-2 Negative Breast Cancer Patients
N/ARecruitingFudan University
0
impact
A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer After Taxane Failure
Phase 3ActiveSichuan Baili Pharmaceutical Co., Ltd.
0
impact
A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of FDA022-BB05 in Patients with Advanced/Metastatic Solid Tumors
Phase 2RecruitingShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
0
impact
A Phase 1, Multicenter, Open-label First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of SKB518 in Subjects With Advanced Solid Tumors
Phase 1RecruitingSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Study Chair
0
impact
A Phase 3, Open-label, Randomised Study of FDA018-ADC Versus Investigator's Choice of Chemotherapy in Patients Who Recurred During or After Taxane Therapy in Locally Advanced or Metastatic Triple-negative Breast Cancer
Phase 3ActiveShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
0
impact
A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-NKT in the Treatment of Relapsed or Metastatic Advanced Renal Cell Carcinoma.
Phase 1UnknownFudan University
0
impact
Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of JSKN003 in Chinese Subjects With Advanced Solid Tumors
Phase 2ActiveJiangsu Alphamab Biopharmaceuticals Co., Ltd
0
impact
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Initial Efficacy of BL-M07D1 for Injection in Patients With Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
Phase 1RecruitingSichuan Baili Pharmaceutical Co., Ltd.
0
impact
A Phase I Study Evaluating Safety and Tolerability of RGT-419B Monotherapy in Chinese Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer or Other Solid Tumors
Phase 1ActiveRegor Pharmaceuticals Inc.
0
impact
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-452080 in Subjects With Solid Tumors
Phase 1UnknownBetta Pharmaceuticals Co., Ltd.
0
impact
A Phase I Dose Escalation Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Biological Properties of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Patients With Advanced Malignant Solid Tumors
Phase 1ActiveHangzhou Converd Co., Ltd.
0
impact
A Phase I Clinical Study to Evaluate Safety and Efficacy of C-TIL052A Cell Therapy (Autologous Tumor Infiltrating Lymphocytes Injection Combined With IL-2) in Subjects With Persistent, Recurrent and/or Metastatic Cervical Cancer
Phase 1UnknownFudan University
0
impact
Phase I/II Clinical Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Antitumor Activity of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 2SuspendedMabwell (Shanghai) Bioscience Co., Ltd.
0
impact
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX53 (an Anti-TIGIT Fc Fusion Protein) in Patients With Advanced/Metastatic Solid Tumors
Phase 1UnknownShanghai Henlius Biotech
0
impact
Incidence and Prognostic Significance of HER-2 Status Discordance Between Primary Breast Cancer and Paired Recurrent/Metastatic Lesions
N/ACompletedFudan University
0
impact
A Multicenter, Open-label, Phase Ib Clinical Trial of GB491 in Combination With Letrozole in Previously Untreated Patients With HR-positive, HER2-negative Advanced Breast Cancer
Phase 1UnknownGenor Biopharma Co., Ltd.
0
impact
A Phase II, Single-center, Randomized Study of Eribulin Plus Cisplatin (EP) Versus Gemcitabine Plus Cisplatin (GP) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer
Phase 2UnknownFudan University
0
impact
Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer: a muLti-centEr Phase II Study
Phase 2CompletedFudan University
0
impact
Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer
Phase 2UnknownFudan University
0
impact